AbbVie: Who we are At AbbVie, we strive to make a remarkable impact on the lives of patients.
AbbVie: Who we are US-ABBV-200135 2 AbbVie has as long history in healthcare dating back to 1888 with Abbott 130+ years of patient care
Launched as AbbVie in 2013
Millions of lives touched
AbbVie: Who we are US-ABBV-200135 3 AbbVie’s Mission
Create an innovation-driven, patient- focused specialty biopharmaceutical company capable of achieving sustainable top-tier performance through outstanding execution and a consistent stream of innovative new medicines which have a remarkable impact on people’s lives.
AbbVie:AbbVie: Who we Who are we are US - ABBV US--ABBV200135-200135 4 With Allergan, AbbVie has an expanded global footprint of state-of-the-art facilities
Ireland: Ballytivnan Cork Sligo Ireland: Dublin Michigan, USA Galway Illinois, USA: Wyandotte Lake County Westport North Chicago New Jersey, USA: Branchburg Ludwigshafen, Germany California, USA: Madison Redwood City Massachusetts, USA: Marlow, United Kingdom San Francisco Cambridge Sunnyvale Worcester Pringy, France
California, USA: Cincinnati, OH, USA Campbell Grâce-Hollogne, Belgium Dublin/Pleasanton Barceloneta, Irvine Puerto Rico (2) Campoverde, Italy Texas, USA: Houston Tokyo, Japan Waco Singapore, Singapore Heredia, Costa Rica
Grande Guarulhos, Brazil
AbbVie facilities
Allergan facilities *Not all sites pictured AbbVie: Who we are US-ABBV-200135 5 We have market leadership in attractive growth segments #1 #2 Immunology Hematologic oncology
Leadership in Women’s #1 health Aesthetics
#1 Leadership in Eye care Global HCV
AbbVie: Who we are US-ABBV-200135 6 Therapeutic areas of focus: Immunology
We leverage deep scientific expertise to develop next-generation biologics and small molecules in rheumatology, dermatology and gastroenterology. AbbVie medicines in immunology currently treat +1 million patients in 15 indications worldwide.
AbbVie: Who we are US-ABBV-200135 7 Therapeutic areas of focus: Oncology
Current treatment areas: Acute Myeloid Leukemia Chronic Graft vs Host Disease Chronic Lymphocytic Leukemia Mantle Cell Lymphoma Marginal Zone Lymphoma Waldenstrom’s Macroglobulinemia
Future areas of focus: Immuno-oncology Apoptosis/B-cell receptor field
AbbVie: Who we are US-ABBV-200135 8 Therapeutic areas of focus: Neuroscience
We’re researching and developing new, innovative, disease-modifying solutions to address some of the most difficult-to-treat neurodegenerative diseases.
Diseases: Additional Indications: • Alzheimer’s disease • Adult Focal Spasticity • Bipolar disorder • Blepharospasm • Bipolar Depression • Cervical Dystonia • Chronic migraine • Pediatric Upper Limb • Multiple sclerosis Spasticity • Overactive bladder • Severe Axillary • Parkinson’s disease Hyperhidrosis • Schizophrenia • Strabismus
AbbVie: Who we are US-ABBV-200135 9 Therapeutic areas of focus: Eye Care
Currently treating: Glaucoma Ocular hypertension Other conditions
Researching areas: Retina-related diseases, such as macular edema Diabetic macular edema Age-related macular degeneration
AbbVie: Who we are US-ABBV-200135 10 Therapeutic areas of focus: Virology
We are the global leader in HCV
Despite the availability of a cure, most people with HCV are untreated and in the earlier stages of liver disease. Together with the HCV community, AbbVie is a committed member of the global movement towards HCV elimination with the goal to eliminate hepatitis C by 2030.
AbbVie: Who we are US-ABBV-200135 11 Other specialties
Focused investments in areas that fit our core strengths include:
Cardiology Gastroenterology General medicine Women’s health
AbbVie: Who we are US-ABBV-200135 12 #1 leadership position with world-renowned brands Current treatments: Body contouring Facial injectables Plastics Regenerative medicine Skin care
AbbVie: Who we are US-ABBV-200135 13 Together, we have even greater ability to meet the needs of patients
AbbVie Therapeutic Areas
Allergan Aesthetics Immunology Oncology Neuroscience Eye Care Virology Women’s Health Other specialty • General medicine
Treating across in more than ~60 30+ 175+ conditions brands countries AbbVie: Who we are US-ABBV-200135 14 AbbVie: Who we are US-ABBV-200135 15 AbbVie: Who we are US-ABBV-200135 16 AbbVie’s Commitment to Corporate Responsibility
Corporate strategy: We strive to make a remarkable impact on patients and drive sustainable growth by discovering and delivering a consistent stream of innovative medicines that address serious health problems.
Creating real health We recognize that health is of For any enterprise to be improvement is not only our fundamental importance to all successful, it must operate in a mission, but also how we stay people. To participate over the healthy business environment. We competitive. To be a leading long term in the provision of have the opportunity to use our health care innovator, we must health care, we must earn and unique resources to support well- attract, retain and support a maintain the trust of patients, being, resilience and growth in the diverse workforce and invest in health care providers, communities where we do their efforts to develop regulators, policymakers, and business and help lay the medicines that bring value for the public. foundation for broader community patients. vitality.
Principles: Driving innovation Transforming lives Acting with integrity Serving the community Embracing diversity and inclusion
Responsibility Commitments: USE OUR EXPERTISE TO STEWARD OUR ETHICAL AND SUPPORT LONG-TERM IMPROVE HEALTH SUSTAINABLE BUSINESS COMMUNITY STRENGTH
AbbVie: Who we are US-ABBV-200135 17 #AbbVieGivesBack: www.abbvie.com/responsibility
Employee Giving Global Week of Philanthropic Engaging Children Supporting Volunteerism Giving in STEM Employees During Pivotal Moments
AbbVie Foundation Week of Dedicated to making The AbbVie The AEAF provides matches employee Possibilities unites a remarkable impact Foundation SEEK scholarships for on the lives of Program introduces donations dollar for AbbVie employees employees’ children underserved by underserved students and financial dollar to nonprofits around the world supporting programs to the nature of assistance for across the globe. with a single that build strong science and employees in times of purpose: to give communities, engineering through disaster or hardship. back to our local effective educational fun, participatory communities. programs and activities. The program sustainable health has been translated care systems. into 12 languages.
AbbVie: Who we are US-ABBV-200135 18 Our commitment to the environment is ongoing
24% of purchased electricity came from renewable sources 10 New environmental sustainability projects approved through SPARK
AbbVie: Who we are US-ABBV-200135 19 External recognition as a top company
Workplace & Diversity Environment, Social Citizenship Business and Governance Performance
DiversityInc. “Top 50 Companies for Dow Jones Sustainability World Civic 50 Diversity” Index FORTUNE 100 FORTUNE “100 Best EcoVadis Corporate Social Corporate Responsibility FORTUNE World’s Most Admired Companies to Work For” Responsibility Assessment Gold Magazine’s “100 Best Corporate Companies Medal Citizens” Great Places to Work “World’s Best IDEA Pharma Innovation Index FTSE4Good Index FORTUNE/Great Place to Work Workplaces” “Best Workplaces for Giving Back” Pharma Reptrak Most Reputable Human Rights Campaign Corporate S&P 500 ESG Index PEOPLE’s “50 Companies That Companies Equality Index Care”
Science Magazine’s Top Employers
Working Mother “100 Best Companies”
AbbVie: Who we are US-ABBV-200135 20 Together, we will innovate for tomorrow, while making a remarkable impact for millions today.
AbbVie: Who we are US-ABBV-200135 21 ® People. Passion. Possibilities.
AbbVie: Who we are US-ABBV-200135